By Dennis Ford, Founder & CEO, Life Science Nation (LSN)
Every March, early-stage life science teams spend thousands of euros to attend one of Europe’s biggest partnering weeks. They show up expecting investors, deal momentum, and progress. Most leave with something else: lots of vendor and service provider meeting requests, and a shorter cash runway.
For seed, Series A, and early Series B companies, Lisbon is not a winter party celebration. It is a stress test. And the platforms you choose will either compound your progress or quietly drain your capital.
The Cost Reality No One Likes to Say Out Loud
Standard passes and bundled “week in Lisbon” packages routinely run from 3,000 to 5,000 euros per person, before flights and hotels. For late-stage companies, that may be acceptable. For early-stage teams living on grants, founder savings, or a small seed round, it is a major bet.
By contrast, RESI Europe is typically priced in the 1,500-2,500 euro range because it is built specifically for founders, innovators, and regional cohorts raising seed, Series A, and early Series B funding. The goal is not to sell access at any cost. It is to make high-quality global partnering economically accessible at a stage when every euro still must justify itself.
Here is the problem. Many founders pay the higher prices and then discover that a large share of their so-called “investor” meetings are with service providers selling you something. The badge may say partner or advisor, but the economics are reversed. The startup becomes the customer, not the one being backed.
That outcome is not accidental. It is how large conference ecosystems monetize scale.
Lisbon Does Not Create Strategy. It Exposes It.
Big conference weeks amplify whatever strategy you bring. If you arrive without preparation and focus, you get more noise, more meetings you did not need, and a bigger bill. If you arrive with discipline, targeted investors, and a follow-up system, Lisbon can work.
The problem is that most mega-events are optimized for volume, not readiness. More people. More meetings. More urgency. That model works for late-stage transactions. It fails early-stage teams.
Early-stage companies need fewer things done well:
- Investors and licensing partners who write first checks
- Fewer vendor-driven meetings
- A way to turn first conversations into real follow-up and progress
Proof That a Different Model Works
At JPM Week in January, RESI was designed explicitly around early-stage investing. Roughly 800 companies actively seeking capital and licensing deals participated alongside more than 800 qualified investors and licensing partners from around the world.
Participation was not open-ended. Investor categories were defined. Registrations per firm were capped to protect the signal in the room. The result was not fewer meetings. It was better, more compelling meetings.
That same discipline is what matters in Lisbon.
Why the LSN Partnering Backbone Beats Scale
LSN, owner of the RESI conference series, also owns a premier database of capital investors and licensing partners in the life sciences and offers programs for de-risking early-stage assets and for preparing and executing global roadshows, as well as services like BD Assist, which actually sets up the meetings for you. RESI has five global partnering events annually.
A partnering backbone asks different questions. Are you spending time with partners who fit your stage and product? Have you reduced scientific, regulatory, and execution risk before asking for capital? Do you have a system to re-engage after the week ends? When the answer is yes, Lisbon stops being a gamble.
The Real Fight
The real battle for Lisbon is not about who has the biggest crowd or the loudest brand. It is about who is actually built for early-stage innovation and who is pricing and designing their platform around scale.
For founders, investors, and regions focused on seed, Series A, and early Series B, the smart move is to start the week with early-stage as the priority, not the afterthought, and with “investor” meaning capital and licensing partner, not a sales pitch. Plug Lisbon into a backbone that keeps working after the noise fades. That is how early-stage teams win Lisbon. And that is where the fight really is.
If You’re Coming to Lisbon
RESI Europe will take place in Lisbon with an in-person conference followed by virtual partnering, giving early-stage teams both face-to-face and online access to global investors and licensing partners at founder-level pricing. If you want your Lisbon week to start in a room built for early-stage innovation, not a room selling to you, RESI is where that week should begin.
Tags: AI, business, digital-marketing, entrepreneurship, health, Healthcare, marketing, news, science, startups, technology, venture capital
Next Phase Newsletter 